Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06433752 · ClinicalTrials.gov registry record
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
A clinical trial of Multiple Sclerosis and Relapsing Multiple Sclerosis, sponsored by TG Therapeutics.
- Recruiting
- Registry status
- 500
- Enrollment target
- 20
- Study locations
NCT06433752: Recruiting study of Multiple Sclerosis and Relapsing Multiple Sclerosis, sponsored by TG Therapeutics.
NCT06433752 is a study of Multiple Sclerosis and Relapsing Multiple Sclerosis that is actively recruiting participants, run by TG Therapeutics. The registered enrollment target is 500 participants, below the 583-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (14% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06433752, a study of Multiple Sclerosis and Relapsing Multiple Sclerosis, is actively recruiting participants, sponsored by TG Therapeutics.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate safety, effiectiveness, and to gain insight into the treatment experience of participants prescribed BRIUMVI® (ublituximab-xiiy) in the real-world setting
Conditions Studied
Interventions
- OTHER No Intervention
Study Locations (20)
Colorado
- TG Therapeutics Investigational Trial Site - Aurora
- TG Therapeutics Investigational Trial Site - Basalt
- TG Therapeutics Investigational Trial Site - Colorado Springs
- TG Therapeutics Investigational Trial Site - Denver
- TG Therapeutics Investigational Trial Site - Fort Collins
- TG Therapeutics Investigational Trial Site - Grand Junction
California
- TG Therapeutics Investigational Trial Site - Fresno
- TG Therapeutics Investigational Trial Site - Newport Beach
- TG Therapeutics Investigational Trial Site - Orange
- TG Therapeutics Investigational Trial Site - West Hollywood
Arizona
- TG Therapeutics Investigational Trial Site - Gilbert
- TG Therapeutics Investigational Trial Site - Phoenix
- TG Therapeutics Investigational Trial Site - Scottsdale
Alabama
- TG Therapeutics Investigational Trial Site - Birmingham
- TG Therapeutics Investigational Trial Site - Mobile
Connecticut
- TG Therapeutics Investigational Trial Site - Farmington
- TG Therapeutics Investigational Trial Site - Hartford
Delaware
- TG Therapeutics Investigational Trial Site - Wilmington
District of Columbia
- TG Therapeutics Investigational Trial Site - Washington D.C.
Florida
- TG Therapeutics Investigational Trial Site - Altamonte Springs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2024-07-22 |
| Est. Completion | 2027-07-01 |
What NCT06433752 shows while recruiting
NCT06433752 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, below the 583-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (14% lower).
The record links to 2 conditions, with Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which No Intervention is the first listed.
NCT06433752 names 20 study sites across 8 states, led by Colorado, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT06433752 about?
NCT06433752 is a clinical study titled "A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)". The purpose of this study is to evaluate safety, effiectiveness, and to gain insight into the treatment experience of participants prescribed BRIUMVI® (ublituximab-xiiy) in the real-world setting
What is the current status of trial NCT06433752?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2024-07-22. Estimated completion is 2027-07-01.
What conditions does trial NCT06433752 study?
This clinical trial studies the following conditions: Multiple Sclerosis, Relapsing Multiple Sclerosis.
What interventions are being tested in trial NCT06433752?
The interventions under investigation include: No Intervention (OTHER).
Who is sponsoring clinical trial NCT06433752?
This trial is sponsored by TG Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06433752 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06433752's enrollment target sits among peer trials
500 42nd of 315 higher than 274 of 315 other Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
Prepare the Mind: Can Coaching in Goal-directed Behaviour Increase the Success of Cognitive Rehabilitation in People With MS?
RECRUITING · NA
-
Incremental Vestibulo-ocular Reflex Adaptation as a Novel Treatment for Dizziness in People With Multiple Sclerosis
RECRUITING · NA
-
Vancomycin Study in Multiple Sclerosis (MS)
RECRUITING · Phase 1
-
IConquerMS™ - a Patient-Powered Research Network for Multiple Sclerosis
RECRUITING
-
Prospective Investigation of Multiple Sclerosis in the Three Rivers Region
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI